EP4257194A3 - Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit - Google Patents

Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit Download PDF

Info

Publication number
EP4257194A3
EP4257194A3 EP23182773.4A EP23182773A EP4257194A3 EP 4257194 A3 EP4257194 A3 EP 4257194A3 EP 23182773 A EP23182773 A EP 23182773A EP 4257194 A3 EP4257194 A3 EP 4257194A3
Authority
EP
European Patent Office
Prior art keywords
human
animal health
microbial communities
composition
communities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23182773.4A
Other languages
English (en)
French (fr)
Other versions
EP4257194A2 (de
Inventor
Sam Possemiers
Massimo Marzorati
Tom Van De Wiele
Ilse SCHEIRLINCK
Selin BOLCA
Pieter VAN DEN ABEELE
Davide GOTTARDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Gent
Microbial Resource Management Health NV MRM Health
Original Assignee
Universiteit Gent
Microbial Resource Management Health NV MRM Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Gent, Microbial Resource Management Health NV MRM Health filed Critical Universiteit Gent
Publication of EP4257194A2 publication Critical patent/EP4257194A2/de
Publication of EP4257194A3 publication Critical patent/EP4257194A3/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/26—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pH
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
    • C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
    • C12M41/34—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of gas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/169—Plantarum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/513—Adolescentes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Sustainable Development (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP23182773.4A 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit Pending EP4257194A3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16154288 2016-02-04
PCT/EP2017/052422 WO2017134240A1 (en) 2016-02-04 2017-02-03 Use of microbial communities for human and animal health
EP17703726.4A EP3411052B8 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit
EP19212983.1A EP3639834B1 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP19212983.1A Division EP3639834B1 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit
EP17703726.4A Division EP3411052B8 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit

Publications (2)

Publication Number Publication Date
EP4257194A2 EP4257194A2 (de) 2023-10-11
EP4257194A3 true EP4257194A3 (de) 2023-12-20

Family

ID=55310719

Family Applications (3)

Application Number Title Priority Date Filing Date
EP23182773.4A Pending EP4257194A3 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit
EP19212983.1A Active EP3639834B1 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit
EP17703726.4A Active EP3411052B8 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP19212983.1A Active EP3639834B1 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit
EP17703726.4A Active EP3411052B8 (de) 2016-02-04 2017-02-03 Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit

Country Status (23)

Country Link
US (7) US11096971B2 (de)
EP (3) EP4257194A3 (de)
JP (3) JP7016112B2 (de)
KR (2) KR20250079251A (de)
CN (2) CN116570631A (de)
AU (2) AU2017216285B2 (de)
CA (1) CA3011083A1 (de)
CY (1) CY1123954T1 (de)
DK (2) DK3411052T3 (de)
ES (2) ES2960781T3 (de)
FI (1) FI3639834T3 (de)
HR (1) HRP20231182T1 (de)
HU (2) HUE051114T2 (de)
IL (3) IL293486B2 (de)
LT (2) LT3411052T (de)
MX (1) MX382399B (de)
PL (2) PL3639834T3 (de)
PT (1) PT3639834T (de)
RS (2) RS60918B1 (de)
RU (1) RU2758387C2 (de)
SI (2) SI3639834T1 (de)
SM (1) SMT202000547T1 (de)
WO (1) WO2017134240A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP4257194A3 (de) 2016-02-04 2023-12-20 Universiteit Gent Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit
CN115919906A (zh) * 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
JP7542946B2 (ja) 2016-09-27 2024-09-02 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
US11723935B2 (en) * 2017-02-06 2023-08-15 New York University Methods and compositions for treating and diagnosing pancreatic cancers
CN107384828B (zh) * 2017-08-22 2020-06-16 中国农业科学院农产品加工研究所 阿克曼氏粘细菌培养基及其制备方法
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
KR102250597B1 (ko) 2017-11-20 2021-05-11 경희대학교 산학협력단 신규 유산균 및 이의 용도
WO2019098810A2 (ko) * 2017-11-20 2019-05-23 경희대학교 산학협력단 신규 유산균 및 이의 용도
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
AU2019253616A1 (en) * 2018-04-13 2020-11-05 Med-Life Discoveries Lp Long chain dicarboxylic fatty acid (LCDFA) producing microbes and uses thereof
CA3098968A1 (en) * 2018-05-04 2019-11-07 4D Pharma Research Limited Simulated intestinal environment
CA3106315A1 (en) * 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
US11859214B1 (en) 2018-08-17 2024-01-02 The Government Of The United States, As Represented By The Secretary Of The Army Automated system for simulating the human lower gastrointestinal tract
EP3870691A4 (de) * 2018-09-13 2022-09-07 Xbiome Inc. Verfahren und zusammensetzungen zur behandlung von gastrointestinalen und entzündlichen erkrankungen
WO2020079026A1 (en) * 2018-10-15 2020-04-23 Pharmabiome Ag A method of manufacturing a consortium of bacterial strains
CN113271796A (zh) * 2018-11-05 2021-08-17 芝加哥大学 用于治疗感染性、自身免疫和过敏性疾病的方法和组合物
WO2020106983A1 (en) 2018-11-21 2020-05-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
JP2022517268A (ja) * 2019-01-16 2022-03-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 免疫チェックポイント阻害剤関連大腸炎を処置するための方法および組成物
US12290538B2 (en) 2019-07-19 2025-05-06 Finch Therapeutics Holdings Llc Methods and products for treatment of gastrointestinal disorders
CN110607262B (zh) * 2019-09-25 2022-03-25 君维安(武汉)生命科技有限公司 一种干预炎性肠炎的益生菌组合物及其筛选方法和应用
CN110448577B (zh) * 2019-09-26 2023-06-23 青岛农业大学 一种溃疡性结肠炎修复益生菌微胶囊制剂
KR20220108765A (ko) 2019-10-07 2022-08-03 시올타 테라퓨틱스, 인크. 치료용 약학 조성물
US20220354855A1 (en) * 2019-10-09 2022-11-10 Mayo Foundation For Medical Education And Research Treatment for gastrointestinal disorders
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
CN110916192B (zh) * 2019-11-25 2021-04-13 垒途智能教科技术研究院江苏有限公司 一种具有防治儿童青少年自闭症的益生菌矿物粉及其应用
CN114828867A (zh) * 2019-12-13 2022-07-29 株式会社明治 降低心率用组合物
MX2022007796A (es) 2019-12-23 2023-01-24 Evonik Operations Gmbh Preparacion que comprende cepas probioticas para la degradacion del gluten.
CN111281895A (zh) * 2019-12-24 2020-06-16 顾青 用于治疗结肠炎的乳酸菌及其应用
CN111117925B (zh) * 2020-01-13 2021-05-25 浙江大学 Anaerostipes sp B2131菌及其在炎症性肠病中的应用
CN111413503A (zh) * 2020-03-28 2020-07-14 浙江大学 骨桥蛋白作为靶分子在调节高脂饮食引起的肥胖中的应用
JP7663322B2 (ja) * 2020-04-08 2025-04-16 雪印メグミルク株式会社 ビフィズス菌増殖促進剤
KR20220164034A (ko) * 2020-04-08 2022-12-12 유키지루시 메그밀크 가부시키가이샤 장내 세균총 개선용 조성물
KR20220164594A (ko) * 2020-04-08 2022-12-13 소마젠 인크 미생물총 내 항생제 유발 불균형에 대한 조성물 및 방법
KR102169794B1 (ko) * 2020-06-24 2020-10-27 주식회사 엔테로바이옴 신규한 피칼리박테리움 프로스니치 균주 eb-fpdk11 및 그의 용도
CA3188645A1 (en) * 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
CN111938158B (zh) * 2020-08-18 2023-07-07 广东弘元普康医疗科技有限公司 一种防止肠道Akkermansia muciniphila菌丰度降低的组合物
CN112080445A (zh) * 2020-08-20 2020-12-15 浙江工商大学 植物乳杆菌zj316和在抑制幽门螺旋杆菌方面的应用
JP2022052715A (ja) * 2020-09-23 2022-04-04 雪印メグミルク株式会社 腸内細菌叢改善用組成物
GB202015687D0 (en) * 2020-10-02 2020-11-18 Microbiotica Ltd Therapeutic composition
CN113215020B (zh) * 2021-02-22 2022-06-17 中国科学院微生物研究所 罗氏菌mgb-2及其应用
CN113214976B (zh) * 2021-03-29 2023-04-14 中南大学 一种高效筛选嗜酸微生物的装置及其筛选方法
BE1029496B1 (fr) * 2021-08-19 2023-01-16 The Akkermansia Company Composition comprenant de l'Akkermansia muciniphila pasteurisée pour le traitement ou la prévention des troubles de la contractilité intestinale, en particulier des troubles de l'amplitude de la contractilité duodénale
EP4405509A4 (de) * 2021-09-20 2025-10-22 Hudson Inst Med Res Biotherapeutische enterococcus isolate
KR20240130121A (ko) 2021-12-27 2024-08-28 엠알엠 헬스 엔.브이. 미생물 군집
CN114292781B (zh) * 2021-12-28 2023-08-01 中山大学 一种长双歧杆菌sysu-02及其应用
CN114304380A (zh) * 2022-01-13 2022-04-12 合肥河川生物医药科技有限公司 普拉梭菌在猪鸡上的应用
NL2032642B1 (en) * 2022-07-29 2024-02-06 Academisch Ziekenhuis Leiden Improvement of muscle mass and strength
WO2024049207A1 (ko) * 2022-08-31 2024-03-07 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN115737687A (zh) * 2022-10-16 2023-03-07 新疆医科大学第一附属医院 普拉梭菌在制备预防或/和治疗冠心病药物或/和保健品中的应用
CN116004440B (zh) * 2022-10-25 2025-06-13 深圳未知君生物科技有限公司 一株粘膜粘液乳杆菌及其在制备治疗癌症的药物中的应用
WO2024123891A1 (en) * 2022-12-07 2024-06-13 The University Of North Carolina At Chapel Hill Office Of Technology Commercialization Engineered microorganism compositions and applications thereof
AU2023201304B2 (en) * 2023-03-02 2026-02-26 Kemin Industries, Inc. Methods and compositions for improving food safety and enhancing feed efficiency in poultry
EP4719091A1 (de) * 2023-05-31 2026-04-08 The Regents Of The University Of California Zusammensetzungen und verfahren zur behandlung von geistes- und stoffwechselerkrankungen
CN116836880B (zh) * 2023-07-24 2023-11-28 中山大学 一种普氏梭杆菌及其应用
CN116925975B (zh) * 2023-08-18 2024-01-23 善恩康生物科技（苏州）有限公司 一种Akkermansia muciniphila及其产品和应用
WO2025100480A1 (ja) * 2023-11-08 2025-05-15 慶應義塾 組成物、飲食品、及び病原性細菌又は病原性真菌に起因する疾患の検査及び診断を補助する方法
WO2025183115A1 (ja) * 2024-02-28 2025-09-04 三菱ケミカル株式会社 乳酸産生菌及び酪酸産生菌を含む整腸用組成物
CN118421503B (zh) * 2024-04-12 2025-02-11 善恩康生物科技（苏州）有限公司 一株新型Akkermansia muciniphila及其应用
CN118489883A (zh) * 2024-05-10 2024-08-16 河北弗蒙特生物科技有限公司 嗜黏蛋白阿克曼氏菌发酵物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036230A1 (en) * 2005-09-28 2007-04-05 Nordisk Rebalance A/S Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors
WO2014137211A1 (en) * 2013-03-05 2014-09-12 Rijksuniversiteit Groningen Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307026D0 (en) * 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
CN101353633B (zh) 2008-06-13 2011-12-28 浙江工商大学 Lactobacillus plantarum ZJ316、产生的抗菌肽及其制备与应用
GB0903016D0 (en) 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
BR112012011294B1 (pt) * 2009-11-12 2018-03-20 Nestec S.A. Composição nutricional para administração a um indivíduo
US8445226B2 (en) * 2010-02-01 2013-05-21 Microbios, Inc. Process and composition for the manufacture of a microbial-based product
US20120034198A1 (en) 2010-08-04 2012-02-09 Microbios, Inc. Carriers for storage and delivery of biologics
WO2012142605A1 (en) 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
ES2660775T3 (es) 2011-05-16 2018-03-26 Belano Medical Ag Nuevas bacterias del ácido láctico y composiciones que las contienen contra los resfriados bacterianos
ES2662793T3 (es) 2011-09-14 2018-04-09 Nubiyota Llc Complementos de medio y métodos para cultivar microorganismos anaerobios gastrointestinales humanos
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN103082292B (zh) 2011-11-02 2015-03-04 深圳华大基因研究院 罗斯氏菌(Roseburia)在治疗和预防肥胖相关疾病中的应用
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA3212215A1 (en) 2012-11-23 2014-05-30 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2899925A1 (en) 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
EP2967077A4 (de) 2013-03-15 2016-09-14 Seres Therapeutics Inc Netzwerkbasierte mikrobielle zusammensetzungen und verfahren
US10058576B2 (en) * 2013-10-03 2018-08-28 The Trustees Of The University Of Pennsylvania Compositions and methods comprising a defined microbiome and methods of use thereof
PL236218B1 (pl) 2013-11-13 2020-12-28 Inst Biotechnologii Surowic I Szczepionek Biomed Spolka Akcyjna Zastosowanie kompozycji probiotycznej
EP3074027B1 (de) 2013-11-25 2024-12-18 Seres Therapeutics, Inc. Synergistische bakterielle zusammensetzungen und verfahren zur herstellung und verwendung davon
EP2944696A1 (de) 2014-05-13 2015-11-18 Evonik Degussa GmbH Verfahren zur Herstellung von organischen Verbindungen
SG10201903823QA (en) * 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3150562B1 (de) * 2015-10-01 2022-02-16 Heraeus Quarzglas GmbH & Co. KG Verwendung von optischem filtermaterial aus dotiertem quarzglas sowie das optische filtermaterial enthaltende uv-lampe
EP4257194A3 (de) * 2016-02-04 2023-12-20 Universiteit Gent Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036230A1 (en) * 2005-09-28 2007-04-05 Nordisk Rebalance A/S Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors
WO2014137211A1 (en) * 2013-03-05 2014-09-12 Rijksuniversiteit Groningen Use of faecali bacterium prausnitzii htf-f (dsm 26943) to suppress inflammation.

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"The Impact of Food Bioactives on Health", 1 January 2015, SPRINGER INTERNATIONAL PUBLISHING, Cham, ISBN: 978-3-319-16104-4, article TOM VAN DE WIELE ET AL: "The Simulator of the Human Intestinal Microbial Ecosystem (SHIME?)", pages: 305 - 317, XP055399184, DOI: 10.1007/978-3-319-16104-4_27 *
ANNELIES GEIRNAERT ET AL: "Butyricicoccus pullicaecorum, a butyrate producer with probiotic potential, is intrinsically tolerant to stomach and small intestine conditions", ANAEROBE, vol. 30, 1 December 2014 (2014-12-01), GB, pages 70 - 74, XP055281743, ISSN: 1075-9964, DOI: 10.1016/j.anaerobe.2014.08.010 *
CHENG SUO ET AL: "Effects of lactobacillus plantarum ZJ316 on pig growth and pork quality", BMC VETERINARY RESEARCH, BIOMED CENTRAL, LONDON, GB, vol. 8, no. 89, 25 June 2012 (2012-06-25), pages 1 - 12, XP021107876, ISSN: 1746-6148, DOI: 10.1186/1746-6148-8-89 *
LINDA V. THOMAS ET AL: "Exploring the influence of the gut microbiota and probiotics on health: a symposium report", BRITISH JOURNAL OF NUTRITION, vol. 112, no. S1, 23 June 2014 (2014-06-23), UK, pages S1 - S18, XP055281760, ISSN: 0007-1145, DOI: 10.1017/S0007114514001275 *
MACHIELS KATHLEEN ET AL: "A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis", GUT, BMJ PUBLISHING GROUP, UK, vol. 63, no. 8, 1 August 2014 (2014-08-01), pages 1275 - 1283, XP009186743, ISSN: 1468-3288 *
S. H. DUNCAN ET AL: "Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, vol. 52, no. 6, 1 November 2002 (2002-11-01), GB, pages 2141 - 2146, XP055565436, ISSN: 1466-5026, DOI: 10.1099/ijs.0.02241-0 *
SCHWIERTZ A ET AL: "ANAEROSTIPES CACCAE GEN. NOV., SP. NOV., A NEW SACCHAROLYTIC, ACETATE-UTILISING, BUTYRATE-PRODUCING BACTERIUM FROM HUMAN FAECES", SYSTEMATIC AND APPLIED MICROBIOLOGY, URBAN & FISCHER, AMSTERDAM, NL, vol. 25, no. 1, 1 January 2002 (2002-01-01), pages 46 - 51, XP009035386, ISSN: 0723-2020, DOI: 10.1078/0723-2020-00096 *
SCOTT K P ET AL: "Manipulating the gut microbiota to maintain health and treat disease.", MICROBIAL ECOLOGY IN HEALTH AND DISEASE, vol. 26, 25877, 2015, pages 1 - 10, XP002758936, ISSN: 0891-060X *

Also Published As

Publication number Publication date
RU2758387C2 (ru) 2021-10-28
MX2018009539A (es) 2019-02-11
US11596658B2 (en) 2023-03-07
HUE051114T2 (hu) 2021-01-28
IL293486B2 (en) 2024-04-01
IL293486B1 (en) 2023-12-01
RU2018131244A (ru) 2020-03-04
EP3411052B8 (de) 2020-09-30
DK3639834T5 (da) 2024-08-26
CN116570631A (zh) 2023-08-11
DK3411052T3 (da) 2020-10-12
EP3639834B1 (de) 2023-07-12
HUE063584T2 (hu) 2024-01-28
US20230028557A1 (en) 2023-01-26
RU2018131244A3 (de) 2020-06-18
EP3639834A1 (de) 2020-04-22
MX382399B (es) 2025-03-13
HK1257070A1 (zh) 2019-10-11
WO2017134240A1 (en) 2017-08-10
SMT202000547T1 (it) 2020-11-10
US20190015465A1 (en) 2019-01-17
JP7460979B2 (ja) 2024-04-03
IL283594A (en) 2021-07-29
KR20180127972A (ko) 2018-11-30
US20210353694A1 (en) 2021-11-18
PT3639834T (pt) 2023-10-12
CY1123954T1 (el) 2022-03-24
LT3639834T (lt) 2023-11-10
RU2021130638A (ru) 2021-11-18
DK3639834T3 (da) 2023-10-09
US12458672B2 (en) 2025-11-04
IL260337A (en) 2018-08-30
JP2024028833A (ja) 2024-03-05
US20220023357A1 (en) 2022-01-27
HRP20231182T1 (hr) 2024-01-05
SI3411052T1 (sl) 2021-01-29
LT3411052T (lt) 2021-01-11
PL3411052T3 (pl) 2021-03-08
EP3411052B1 (de) 2020-07-08
JP7016112B2 (ja) 2022-02-04
US20220040245A1 (en) 2022-02-10
ES2824536T3 (es) 2021-05-12
CN108712906A (zh) 2018-10-26
IL283594B (en) 2022-06-01
KR102816794B1 (ko) 2025-06-05
JP2022058615A (ja) 2022-04-12
JP7737657B2 (ja) 2025-09-11
JP2019511563A (ja) 2019-04-25
AU2017216285B2 (en) 2023-10-05
IL293486A (en) 2022-08-01
EP4257194A2 (de) 2023-10-11
SI3639834T1 (sl) 2024-02-29
AU2017216285A1 (en) 2018-07-26
CA3011083A1 (en) 2017-08-10
PL3639834T3 (pl) 2024-01-29
AU2023248066B2 (en) 2025-12-11
IL260337B (en) 2021-06-30
US11633440B2 (en) 2023-04-25
US20220072071A1 (en) 2022-03-10
CN108712906B (zh) 2023-06-30
KR20250079251A (ko) 2025-06-04
US11491196B2 (en) 2022-11-08
BR112018015097A2 (pt) 2018-12-26
US20230045069A1 (en) 2023-02-09
RS60918B1 (sr) 2020-11-30
RS64782B1 (sr) 2023-11-30
AU2023248066A1 (en) 2023-11-02
FI3639834T3 (fi) 2023-09-27
US11096971B2 (en) 2021-08-24
EP3411052A1 (de) 2018-12-12
ES2960781T3 (es) 2024-03-06

Similar Documents

Publication Publication Date Title
EP4257194A3 (de) Verwendung von mikrobiellen gemeinschaften für human- und tiergesundheit
ATE421256T1 (de) Probiotische zusammensetzung
AU2021350460A9 (en) Novel lactic acid bacteria and use thereof
EP4364745A3 (de) Neuartige milchsäurebakterien und verwendung davon
MX2024011127A (es) Bacterias acidolacticas novedosas y uso de las mismas.
MX420836B (es) Cepa lactobacillus plantarum kbl396 y uso de la misma.
MX2011012069A (es) Micro-organismos no-replicantes y su efecto inmuno estimulador.
PH12015502416A1 (en) Bacterial strains having antimicrobial activity and biocontrol compositions comprising the same
MY172363A (en) Lipid metabolism and/or sugar metabolism improver containing lactic acid bacterium or treatment product thereof
WO2012149615A3 (en) Polybacterial preparation with health benefits: antioxidant effect, reduction of cholesterol concentration, anti-inflammatory immunomodulating effect and release of bioactive peptides inhibiting angiotensin-converting enzyme
UA107711C2 (en) Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
WO2019004684A3 (ko) 나노화된 김치 유산균을 함유하는 피부 주름 개선 또는 피부 보습용 화장료 조성물
ZA201804863B (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
UA113399C2 (xx) Штам непатогенної грамнегативної бактерії та його застосування в дерматології
WO2019098810A3 (ko) 신규 유산균 및 이의 용도
WO2007023226A3 (fr) Utilisation d'un symbiotique pour le traitement de la dermatite atopique
WO2015121458A3 (fr) Utilisations de compositions comprenant du bifidobacterium animalis ssp. lactis lmg p-28149
FI20075539A0 (fi) Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia
TW200700074A (en) Inducer of t cell apoptosis
Chifiriuc et al. Subinhibitory concentrations of phenyl lactic acid interfere with the expression of virulence factors in Staphylococcus aureus and Pseudomonas aeruginosa clinical strains
WO2007015132A3 (en) Use of specific lactic bacteria for the preparation of immunomodulating compositions
WO2009000875A3 (en) Lactobacillus helveticus bacterium composition for treatment of atopic dermatitis
WO2012021016A3 (ko) 항암 활성을 갖는 락토바실러스 균주 및 이를 활성성분으로 포함하는 항암 활성 조성물
BR112019002023A2 (pt) prevenção ou tratamento de infecções antifúngicas vetorizado por bactérias probióticas
TR201808116T1 (tr) İnsanlarda ve hayvanlarda kullanilmak üzere yeni̇ probi̇yoti̇k başlatici kültür

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3411052

Country of ref document: EP

Kind code of ref document: P

Ref document number: 3639834

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61P0029000000

Ipc: A61K0035741000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/00 20060101ALI20231114BHEP

Ipc: A61K 35/741 20150101AFI20231114BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240213

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MICROBIAL RESOURCE MANAGEMENT HEALTH NV

Owner name: UNIVERSITEIT GENT

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101989

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240613

17Q First examination report despatched

Effective date: 20240626